Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

In the PALOMA-3 study, palbociclib plus fulvestrant demonstrated improved progression-free survival compared with fulvestrant plus placebo in hormone receptor-positive, HER2- endocrine-resistant metastatic breast cancer (MBC). This analysis compared patient-reported outcomes (PROs) between the two t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2016-06, Vol.27 (6), p.1047-1054
Hauptverfasser:	Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., Puyana Theall, K., Bartlett, C.H., Loibl, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Disease-Free Survival Drug-Related Side Effects and Adverse Reactions - pathology endocrine resistance Estradiol - administration & dosage Estradiol - adverse effects Estradiol - analogs & derivatives Female Fulvestrant Humans Middle Aged Original palbociclib Patient Reported Outcome Measures patient-reported outcomes Piperazines - administration & dosage Piperazines - adverse effects Pyridines - administration & dosage Pyridines - adverse effects Quality of Life Receptor, ErbB-2 - genetics Receptors, Estrogen - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!